目的 探討艾愈膠囊聯(lián)合阿那曲唑治療絕經(jīng)后激素受體(HR)陽性乳腺癌的臨床療效。方法 選取2019年1月-2022年1月海南醫(yī)學(xué)院第一附屬醫(yī)院收治的136例絕經(jīng)后HR陽性乳腺癌患者,按隨機(jī)數(shù)字表法分為對照組和治療組,每組各68例。對照組口服阿那曲唑片,1片/次,1次/d。治療組在對照組基礎(chǔ)上口服艾愈膠囊,3粒/次,3次/d。兩組均連續(xù)治療3個月。觀察兩組臨床療效,比較治療前后兩組癌灶最大徑、中醫(yī)癥狀評分、癌癥治療性功能評價量表-乳腺癌(FACT-B)評分以及血清腫瘤標(biāo)志物[糖類抗原15-3(CA15-3)、癌胚抗原(CEA)、組織多肽特異性抗原(TPS)]和腫瘤壞死因子(TNF)-α、白細(xì)胞介素(IL)-8、血管內(nèi)皮生長因子(VEGF)、可溶性E-選擇素(sE-selectin)水平。結(jié)果 治療后,治療組客觀緩解率是38.2%,高于對照組的29.4%,兩組比較差異無統(tǒng)計(jì)學(xué)意義;治療組臨床獲益率是76.5%,顯著高于對照組的60.3%(P<0.05)。治療后,兩組癌灶最大徑均顯著縮小,中醫(yī)癥狀評分均顯著降低,FACT-B評分則均顯著增加(P<0.05);且均以治療組改善更顯著(P<0.05)。治療后,兩組血清CA15-3、CEA、TPS水平均較治療前顯著下降(P<0.05);且均以治療組降低更顯著(P<0.05)。治療后,兩組血清TNF-α、IL-8、VEGF、sE-selectin水平均較治療前顯著下降(P<0.05);且均以治療組降低均更顯著(P<0.05)。結(jié)論 艾愈膠囊聯(lián)合阿那曲唑治療絕經(jīng)后HR陽性乳腺癌的抗腫瘤療效確切,能有效降低患者腫瘤負(fù)荷,減輕癥狀,提高生活質(zhì)量,并可進(jìn)一步改善腫瘤微環(huán)境,且安全性好。

Objective To investigate the clinical efficacy of Aiyu Capsules combined with anastrozole in treatment of postmenopausal hormone receptor (HR) positive breast cancer. Methods A total of 136 postmenopausal HR positive breast cancer patients admitted to the First Affiliated Hospital of Hainan Medical University from January 2019 to January 2022 were selected and divided into control group and treatment group according to random number table method, with 68 cases in each group. Patients in the control group were po administered with Anastrozole Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Aiyu Capsules on the basis of the control group, 3 grain/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, the maximum tumor diameter, TCM symptom score, Cancer Therapeutic Function Evaluation Scale-Breast Cancer (FACT-B) score, serum tumor markers [carbohydrate antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), tissue polypeptide specific antigen (TPS)], tumor necrosis factor (TNF-α), interleukin (IL)-8, vascular endothelial growth factor (VEGF), soluble E-selectin (sE-selectin) in the two groups before and after treatment were compared. Results After treatment, the objective remission rate of the treatment group was 38.2%, which was higher than that of the control group (29.4%), and there was no significant difference between the two groups. The clinical benefit rate of the treatment group was 76.5%, which was significantly higher than that of the control group (60.3%) (P＜0.05). After treatment, the maximum diameter of cancer foci was significantly reduced, and the TCM symptom score was significantly decreased, and the FACT-B score was significantly increased in both groups (P＜0.05). The improvement was more significant in treatment group (P＜0.05). After treatment, the serum levels of CA15-3, CEA, and TPS in two groups were significantly decreased compared with before treatment (P＜0.05). The decrease was more significant in treatment group (P＜0.05). After treatment, serum levels of TNF-α, IL-8, VEGF, and sE-selectin in two groups were significantly decreased compared with before treatment (P＜0.05). In addition, the reduction was more significant in treatment group (P＜0.05). Conclusion Aiyu Capsules combined with anastrozole has definite anti-tumor efficacy in treatment of postmenopausal hormone receptor positive breast cancer, and can effectively reduce the tumor burden, relieve symptoms, improve the life quality, which can further improve the tumor microenvironment with good safety.

R914

海南省自然科學(xué)基金資助項(xiàng)目(819QN369)